Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer — LOTS  

Gastric Cancer Clinical Trial

Official title: A Phase II Trial of Perioperative Chemotherapy With Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Status Recruiting

Clinical Trial Summary

The aim of the trial is to investigate the clinical efficacy and toxicity of perioperative chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who receive a curative surgery.

Clinical Trial Description

The study is an open-label, single-arm, single-country and multi-center phase II investigator-initiated trial. Patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who enroll the trial will receive perioperative chemotherapy with LOTS (14 days as a cycle) 4 cycles every 2 weeks, followed by operation and another 4 cycles every 2 weeks post-operatively. The primary outcome is pathological response or curative resection rate. The secondary outcome includes recurrence-free survival, overall survival, disease control rate, protocol completion rate and adverse events. ;

Related Conditions & MeSH terms

• Adenocarcinoma
• Effects of Chemotherapy
• Gastric Adenocarcinoma
• Gastric Cancer
• Stomach Neoplasms
• Toxicity Due to Chemotherapy

• NCT number: NCT04999332
• Study type: Interventional
• Source: National Cheng-Kung University Hospital
• Contact: Clinical Trial Center, National Cheng-Kung University Hospital
• Phone: +886-6-2353535
• Email: ctcnckuh@mail.hosp.ncku.edu.tw
• Status: Recruiting
• Phase: Phase 2
• Start date: December 10, 2021
• Completion date: December 31, 2025